Skip to content
Screener

Total Equity at other companies

Anika Therapeutics logo
Anika TherapeuticsANIK
$137.28M-7.0%
AVN
AVNSAVNS
$782.1M-6.8%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$311.91M+34.3%
AtriCure logo
AtriCureATRC
$516.43M+11.2%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B+1.3%
Enterprise value$1.29B+21.7%
P/E198.5×
P/S1.4×0.0×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemMarch 31,2026December 31,2025
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, par value $0.001; 250,000,000 shares authorized; 48,328,201 shares issued and 39,309,610 shares outstanding at March 31, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 20254848
Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at March 31, 2026 and December 31, 2025, respectively(227,013)(176,565)
Additional paid-in capital1,073,8091,064,623
Accumulated deficit(196,406)(199,322)
Accumulated other comprehensive income3,4554,327
Total stockholders’ equity653,893693,111
Total liabilities and stockholders’ equity$1,208,534$1,264,917

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s total equity?
Pacira BioSciences, Inc. (PCRX) reported total equity of $653.89M in Q1 2026.
How has Pacira BioSciences, Inc.'s total equity changed year-over-year?
Pacira BioSciences, Inc.'s total equity decreased by 18.1% year-over-year, from $798.54M to $653.89M.
What is the long-term trend for Pacira BioSciences, Inc.'s total equity?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s total equity has grown at a 2.3% compound annual growth rate (CAGR), from $619.69M to $693.11M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Pacira BioSciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude